Missionomics Back to app

Healthcare

West Pharmaceutical Services, Inc. (WST)

Healthcare $25.3B market cap

Data as of July 13, 2026

Environment
70.00
People
78.00
Leadership
82.00

Environment story

West discloses limited quantitative emissions data. Scope 1 and 2 emissions are not prominently reported in 10-K; Scope 3 emissions undisclosed. The company states a climate and GHG reduction strategy incorporating renewable energy and reduced absolute emissions as a long-term strategic priority, but no explicit net-zero target year is disclosed. Risk factors acknowledge climate change regulation and potential compliance costs. No evidence of major environmental fines or toxic-waste controversies in recent filings. Deduction applied for undisclosed Scope 3 and absence of explicit net-zero target date. No verified on-site decarbonization infrastructure investments disclosed beyond renewable energy procurement intent.

Criticisms on file

  • PFAS Regulation Risk
    Source: WST 10-K Item 1A Risk Factors: EU and US states considering restrictions or bans on per and polyfluoroalkyl substances (PFAS) in packaging; potential adverse business impact if non-compliance or mandatory material substitution required.
  • Climate Regulation Compliance Costs
    Source: WST 10-K Item 1A Risk Factors: Acknowledgment that foreign, state and local regulatory bodies propose measures to increase GHG transparency, regulate emissions, and implement energy/recycling policies; could incur increased energy, environmental, and capital expenditure costs.
  • Water Scarcity and Extreme Weather Risk
    Source: WST 10-K Item 1A Risk Factors: Manufacturing disruptions possible from extreme weather, water scarcity, and longer-term climatic changes; potential adverse impact on operations and reputation.

Disclosed initiatives

  • Climate and GHG Reduction Strategy
    Long-term strategic priority listed in 2025 10-K includes renewable energy procurement and reduced absolute emissions; managed by corporate sustainability team led by General Counsel.
  • Supply Chain Sustainability
    Commitment to developing more sustainable and responsible supply chain as part of long-term strategic priorities; alignment with Pharmaceutical Supply Chain Initiative (PSCI) standards.
  • Waste and Water Reduction
    Reducing waste to landfill and lowering water intensity in operational processes listed as long-term strategic priorities.

Social story

West employs ~10,800 people globally with 37% female workforce (disclosed). Board composition shows 36% gender diversity and 9% ethnic diversity, indicating room for improvement in executive/technical leadership diversity. No CEO-to-median-worker pay ratio disclosed in proxy or 10-K; unable to assess against 200:1 threshold. No recent NLRB complaints, strikes, or documented union-suppression activities reported. Company maintains safety and health as cultural priority with HSE Governance Council and proactive hazard identification. Turnover rate not disclosed. Supply chain labor practices aligned with PSCI and Business Partner Code of Conduct; no specific human-rights hazards (e.g., conflict minerals) disclosed as unmitigated.

Criticisms on file

  • Limited Disclosed Diversity Metrics
    Source: WST 2026 Proxy Statement: Board 36% gender diverse and 9% ethnically diverse; company-wide workforce 37% female; specific representation in executive and technical leadership roles not disclosed.

Disclosed initiatives

  • Health, Safety and Wellness Program
    HSE Governance Council oversees safety; SEE-DO-SAY program trains and empowers employees to identify and mitigate risk proactively; Leading Indicator and Hazard Identification programs drive improved safety performance.
    Safety described as cultural priority; no material incidents reported.
  • Talent Development and Learning
    Tuition reimbursement program and online learning catalog with 50,000+ courses; continuous learning encouraged; on-the-job and instructor-led training in multiple languages.
  • Diversity, Inclusion and Collaboration Strategy
    Focus on inclusion, collaboration and innovation strategies to create more opportunities and access to talent; Board actively considers gender, race and ethnicity in director nomination process.
    Board 36% gender diverse; diversity metrics still below industry best practice thresholds.
  • Comprehensive Total Rewards Program
    Competitive compensation and benefits designed to attract and retain talent; health care, retirement savings, paid time off, flexible work schedules, Global Employee Assistance Program, Employee Stock Purchase Plan.
  • Business Partner Code of Conduct and PSCI Alignment
    Commitment to Pharmaceutical Supply Chain Initiative standards; prohibitions against forced labor, bonded labor, child labor; updated July 2025 with enhanced supply-chain and data-privacy expectations.
    Covers supplier, vendor, consultant and contractor conduct aligned with modern slavery and labor standards.

Governance story

West maintains robust independent Board oversight with 10 of 11 directors determined independent; only CEO/Chair Eric Green is non-independent. Lead Independent Director (Robert Friel, elected April 2025) has clearly defined authority and responsibilities per Bylaws and Corporate Governance Principles. 100% of standing committees are independent. Single-class share structure (no dual-class voting rights). Board conducts annual self-evaluations and reevaluates leadership structure annually; maintained combined Chair/CEO with Lead Independent Director in February 2026 review, citing efficient decision-making and strong oversight. Annual majority voting in uncontested elections; no poison pill; proxy access bylaw in place. Board adopted comprehensive governance documents including Code of Conduct (updated July 2025), Business Partner Code of Conduct, and Supply Chain Policy aligned with UK modern slavery law. No direct political contributions made in 2025; company monitors trade association policy positions for alignment. Anti-hedging and anti-pledging policies in place; no exceptions granted. No material antitrust, consumer-safety, or financial-fraud proceedings disclosed. Shareholder proposal filed (Proposal 4) requesting mandatory Independent Board Chair policy; Board unanimously recommends vote AGAINST, citing governance flexibility and strong existing oversight structures.

Criticisms on file

  • Shareholder Proposal on Independent Board Chair (Proposal 4)
    Source: WST 2026 Proxy Statement page 75-78: John Chevedden, beneficial owner for 3+ years, filed proposal requesting mandatory separation of Chair and CEO roles and requirement that Chair be independent director. Board unanimously recommends AGAINST. Shareholder acknowledgment that West stock fell from $468 in 2022 to $272 in late 2025. Engagement outreach indicated shareholders representing ~36% of shares accepted call opportunity and expressed appreciation for Board's governance flexibility.

Disclosed initiatives

  • Lead Independent Director Authority
    Robert Friel elected Lead Independent Director April 2025 (succeeded Paolo Pucci). Bylaws and Corporate Governance Principles fully empower Lead Director with authority to: preside at independent director sessions, set agendas, review meeting minutes, call meetings, communicate CEO evaluation results, and lead discussion on sensitive topics.
    Ensures independent oversight and mitigation of Chair/CEO conflicts of interest.
  • Code of Conduct and Compliance Program
    Comprehensive Code of Conduct updated July 2025; covers ethical business conduct, conflicts of interest, diversity/equal opportunity, environment/health/safety, intellectual property protection, and regulatory compliance. Business Compliance and Integrity Program periodically updated per DOJ and HHS OIG guidance. General Counsel/Chief Compliance Officer reports quarterly to Audit Committee.
    Establishes ethical and regulatory compliance framework; mandatory for all team members, officers and directors.
  • Business Partner Code of Conduct and Supply Chain Governance
    Supply Chain Policy Statement adopted per UK modern slavery law requirements (similar to California); Business Partner Code of Conduct updated July 2025; PSCI alignment; prohibition on forced, bonded, indentured labor; expectations for vendors, suppliers, consultants, contractors on ethics, data privacy and AI use.
    Establishes governance and ethics expectations across supply chain; alignment with industry standards.
  • Related Party Transaction Policy
    Board-adopted policy establishes clear guidelines for review, approval and disclosure of transactions with related persons (directors, officers, 5% shareholders and immediate family). NCGC reviews material facts and determines materiality of interest; pre-approves certain transaction types.
    No related person transactions required to be reported under SEC rules as of 10-K filing.
  • Board and Committee Self-Evaluations
    Annual evaluations assess Board and Committee effectiveness; managed by NCGC; includes annual reevaluation of Board leadership structure.
    Supports continuous governance improvement; flexibility to adjust leadership structure if warranted.
  • Director Qualification Standards and Independence Standards
    Board-adopted Independence Standards meet or exceed NYSE listing standards; explicitly define independent director criteria; reviewed annually by NCGC and affirmed by Board.
    Ensures rigorous independence assessment and transparency.
  • Anti-Hedging and Anti-Pledging Policies
    Directors, officers and employees prohibited from hedging, monetizing, pledging or hypothecating Company securities without prior General Counsel clearance (exceedingly rare). No short sales or margin accounts permitted. No exceptions or waivers granted.
    Prevents speculative trading and conflicts of interest; aligns with insider trading law compliance.
  • Share Ownership Guidelines
    Directors required to acquire and retain shares equal to 5x annual retainer within 3 years of appointment. Officers required to acquire shares per multiples of base salary (CEO 6x, CFO 3x, other officers 2x) within 5 years of assuming position.
    Aligns director and officer interests with shareholder interests; encourages long-term perspective.
  • Executive Officer Succession Planning
    Comprehensive succession planning overseen by Board, CEO and Chief Human Resources Officer. Annual review of senior management; assessment of leadership capabilities, development plans, retention. Detailed CEO succession plans reviewed annually. Board interacts with leadership pipeline candidates. CEO Eric Green informed Board March 6, 2026 of intent to retire once successor hired; search underway with executive recruiting firm; transition expected H2 2026.
    Ensures organizational stability and leadership continuity; addresses planned CEO transition.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of West Pharmaceutical Services, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open West Pharmaceutical Services, Inc. in the app for interactive charts and portfolio building.

Open West Pharmaceutical Services, Inc. in Missionomics

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)

Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics